Mestinon Tablet (Pyridostigmine Bromide)

Adult dose

Adults: Administer orally in 3 divided doses, for a total daily dose of 60~180㎎ of pyridostigmine bromide. Adjust the dose as appropriate according to age and symptoms.

This medication should not be used in certain patients. For example, individuals who are allergic to this drug or similar drugs should not take it. Patients with obstructive or narrow conditions in the gastrointestinal tract or urinary tract, or those with spasms should also avoid this medication. Caution is also necessary for individuals with bronchial asthma or spastic bronchitis. Patients with iritis (inflammation of the eye), those with hyperthyroidism, individuals with muscle tension abnormalities, and patients with Parkinson's disease should also avoid this medication. Patients in a state of shock after surgery or those with cardiovascular issues, patients receiving certain muscle relaxants, and those with vagal nerve tension should not use this medication. Patients with impaired kidney function, those who have had peptic ulcers or gastric surgery, diabetic patients, and individuals with liver damage should exercise particular caution when using this medication. Regular liver function tests are recommended during the treatment. Patients with weak heart function, those who have recently experienced a myocardial infarction, individuals with arrhythmias or bradycardia, patients with hypotension, coronary artery occlusion, or epilepsy also need to be careful when using this drug. Additionally, this medication contains certain dyes, so those allergic to these components should also take caution. Side effects may occur while taking this medication. In cases of overdose, symptoms such as respiratory muscle paralysis, abdominal pain, diarrhea, excessive sweating, and pupil constriction may appear, requiring immediate cessation of the medication and notification to medical personnel. Symptoms such as abdominal pain, nausea, vomiting, excessive salivation, tears, sweating, increased bronchial secretions, and increased intestinal motility may also occur. There have also been reports of muscle cramps or weakness, headaches, palpitations, tinnitus, and skin rashes. In particular, patients with myasthenia gravis may experience a sudden worsening of symptoms, so it is important to closely monitor any changes in symptoms and take appropriate action based on these observations. As this medication is primarily excreted by the kidneys, individuals with reduced kidney function should adjust their dosage accordingly. Caution is also needed when using this medication in conjunction with others. When taken with certain muscle relaxants, the effect may be intensified, and when combined with anticholinergic agents, the side effects of this medication may be masked. Women who are pregnant or may become pregnant should only use this medication when the benefits outweigh the risks, as its safety has not been established. Women who are breastfeeding should also use this medication only when absolutely necessary and ideally discontinue breastfeeding if possible. Elderly patients may have reduced kidney function which could increase drug concentration; therefore, a lower starting dose is advisable with careful monitoring.

• Respiratory muscle paralysis
• synkinetic spasms
• abdominal pain
• diarrhea
• sweating
• flaccidity
• miosis
• nausea
• vomiting
• abdominal distention

This medication should be stored in a tightly closed container to prevent air or moisture from entering, recommended to be kept at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication.

Appearance

Orange round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle